Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- FDA Approves Eisai’s Aloxi for Pediatric Indication, Grants Additional Six-Month Exclusivity
June 2, 2014
- Announcement: 1st Annual Real World Data Japan 2014 - Tokyo Marriott Hotel, July 15-16
June 2, 2014
- Suglat Secures Top Position in Anterio’s “Mind Share” Ranking in Both GP, HP Markets in April
June 2, 2014
- Astellas, MSD Report 133 ADRs at EPPV for Suglat between January and April
June 2, 2014
- Takeda, US Biotech Venture Agree to Develop, Commercialize Autoimmune Disease Treatment
May 30, 2014
- Europe Approves Takeda’s UC, CD Treatment Entyvio
May 30, 2014
- Daiichi Sankyo to Tout Quick Cardiac Event Reduction for Efient
May 30, 2014
- Bayer Seeks New VTE Indication for Xarelto in Japan
May 30, 2014
- Atypical Antipsychotic Drug Asenapine Significantly Improves Symptoms of Schizophrenia in PIII Trial; Meiji Seika Pharma
May 30, 2014
- Introduction of Joint Bidding System to Result in 100% Price Agreement Rate by September: Mr Takada of Qol
May 30, 2014
- Eisai Receives Positive Opinion from CHMP on Expanded Indication for Halaven for Second-Line Treatment of Advanced Breast Cancer
May 30, 2014
- Shire Japan to Independently Launch Orphan Drug around September
May 29, 2014
- NDA for Once-Yearly Zoledronic Acid Injection Expected in FY2015: Asahi Kasei Pres. Asano
May 29, 2014
- Daiichi Sankyo’s Antiplatelet Agent Efient Now Available in Japan
May 28, 2014
- Novartis to Divest Flu Vaccine Biz within 18 Months
May 28, 2014
- DSP Grants Daiichi Sankyo Commercialization Rights to Lurasidone in South America
May 28, 2014
- GSK Files Long-Acting COPD Drug for Approval in Japan
May 27, 2014
- Taisho Toyama to Center on Safety for Lusefi Promotion: Product Manager
May 27, 2014
- GSK Launches Tenozet, a First-Line Option for the Treatment of Chronic Hepatitis B
May 27, 2014
- DSP Ceases PIII Colorectal Cancer Trial for Anticancer Agent BBI608
May 27, 2014
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…